Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab plus cisplatin and gemcitabine for KRAS wild-type advanced biliary tract cancer
ACTRN12611000245998Phase 2Completed
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Jul 2012
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab, cisplatin and gemcitabine in biliary cancer, gallbladder adenocarcinoma and Bile duct adenocarcinoma (CCA), sponsored by Australasian Gastro-Intestinal Trials Group. Primary endpoint: Objective clinical benefit. Started Jul 2012; status: completed.
02
Drugs
panitumumabcisplatingemcitabine
03
Conditions
biliary cancergallbladder adenocarcinomaBile duct adenocarcinoma (CCA)
Beyond the preview
Go deeper on ACTRN12611000245998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000245998.